OKYO Pharma
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 3
- Market Cap
- $36.8M
- Introduction
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
- Conditions
- Neuropathic Pain
- Interventions
- Drug: OK-101 0.05%Drug: OK-101 0.1%Drug: Placebo
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Okyo Pharma Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06637527
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Okyo Pharma Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT05759208
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
🇺🇸Butchertown clinical Trials, Louisville, Kentucky, United States
News
OKYO Pharma's Eye Pain Drug Trial Ends Early, Analysts Raise Price Target 60% on Accelerated Timeline
OKYO Pharma's Phase 2 trial for urcosimod, a potential first-in-class treatment for neuropathic corneal pain, closed early after treating 17 patients instead of the planned 48, with top-line results now expected in Q3 2025.
OKYO Pharma Advances Phase 2a Trial for First-Ever Neuropathic Corneal Pain Treatment
OKYO Pharma expects to complete enrollment of 48 patients in its Phase 2a trial of OK-101, the first FDA-cleared investigational drug specifically for neuropathic corneal pain, by Q2 2025.
OKYO Pharma Doses First Subject in Phase II Trial of OK-101 for Neuropathic Corneal Pain
OKYO Pharma has dosed the first subject in its Phase II clinical trial of OK-101 for neuropathic corneal pain (NCP).
OKYO Pharma Doses First Patient in Phase 2 Trial of OK-101 for Neuropathic Corneal Pain
OKYO Pharma has dosed the first patient in its Phase 2 clinical trial evaluating OK-101 for the treatment of neuropathic corneal pain (NCP).